NRx Pharmaceuticals, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -40.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.09 | $-0.18 | -100.0% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.05 | $-0.04 | +20.0% | Beat | |
| Q4 FY25 | not reported | $0.19 | not reported | not reported |
Back to NRXP overview · NRXP holders · NRXP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.